Anti-SV2C monoclonal antibody

Anti-SV2C antibody for FACS & in-vivo assay

Target products collectionGo to SV2C/SV2C products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP1736-Ab-1/ GM-Tg-hg-MP1736-Ab-2Anti-Human SV2C monoclonal antibodyHuman
GM-Tg-rg-MP1736-Ab-1/ GM-Tg-rg-MP1736-Ab-2Anti-Rat SV2C monoclonal antibodyRat
GM-Tg-mg-MP1736-Ab-1/ GM-Tg-mg-MP1736-Ab-2Anti-Mouse SV2C monoclonal antibodyMouse
GM-Tg-cynog-MP1736-Ab-1/ GM-Tg-cynog-MP1736-Ab-2Anti-Cynomolgus/ Rhesus macaque SV2C monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP1736-Ab-1/ GM-Tg-felg-MP1736-Ab-2Anti-Feline SV2C monoclonal antibodyFeline
GM-Tg-cang-MP1736-Ab-1/ GM-Tg-cang-MP1736-Ab-2Anti-Canine SV2C monoclonal antibodyCanine
GM-Tg-bovg-MP1736-Ab-1/ GM-Tg-bovg-MP1736-Ab-2Anti-Bovine SV2C monoclonal antibodyBovine
GM-Tg-equg-MP1736-Ab-1/ GM-Tg-equg-MP1736-Ab-2Anti-Equine SV2C monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP1736-Ab-1/ GM-Tg-hg-MP1736-Ab-2; GM-Tg-rg-MP1736-Ab-1/ GM-Tg-rg-MP1736-Ab-2;
GM-Tg-mg-MP1736-Ab-1/ GM-Tg-mg-MP1736-Ab-2; GM-Tg-cynog-MP1736-Ab-1/ GM-Tg-cynog-MP1736-Ab-2;
GM-Tg-felg-MP1736-Ab-1/ GM-Tg-felg-MP1736-Ab-2; GM-Tg-cang-MP1736-Ab-1/ GM-Tg-cang-MP1736-Ab-2;
GM-Tg-bovg-MP1736-Ab-1/ GM-Tg-bovg-MP1736-Ab-2; GM-Tg-equg-MP1736-Ab-1/ GM-Tg-equg-MP1736-Ab-2
Products NameAnti-SV2C monoclonal antibody
Formatmab
Target NameSV2C
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-SV2C benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species SV2C VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP1736
    Target NameSV2C
    Gene ID22987,75209,29643,706753,488943,101100360,538430,100065509
    Gene Symbol and Synonyms4930527L09Rik,SLC22B3,SV2C
    Uniprot AccessionQ496J9,Q9Z2I6
    Uniprot Entry NameSV2C_HUMAN,SV2C_RAT
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000122012
    Target ClassificationN/A

    The target: SV2C, gene name: SV2C, also named as . Predicted to enable transmembrane transporter activity. Predicted to be involved in chemical synaptic transmission; neurotransmitter transport; and transmembrane transport. Predicted to be located in plasma membrane and synaptic vesicle. Predicted to be active in neuron projection and synaptic vesicle membrane. Predicted to be integral component of synaptic vesicle membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.